EGFR and non-small cell lung carcinoma: In clinical practice, these treatments are superior to platinum-based chemotherapy, as in NSCLC patients with EGFR mutations, the response rate (RR) is 80% and progression-free survival (PFS) can be extended by 10–14 months3,7–10.